Accretion Nutraveda IPO
Market Sentiment
IPO Details
Market Lot Size
IPO Reservation
Financial Analysis
| Metric | 2023 | 2024 | 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 3.07 | 5.20 | 16.06 | 14.07 |
| Expense | 2.78 | 4.28 | 12.87 | 11.20 |
| Profit (PAT) | 0.28 | 0.82 | 2.61 | 2.33 |
| Total Assets | 4.06 | 4.64 | 10.86 | 16.35 |
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Walpar Nutritions Ltd. | 1.80 | 23.94 | 11 |
| Influx Healthtech Limited | 7.31 | 25.93 | 37 |
Promoters: Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 53,20,000 | 100.00% |
| Promoter Holding Post Issue | 72,40,000 | 73.48% |
Strengths & Risks
- Revenue grew 209% in the latest reported year.
- Solid profit margin — 16.3%.
- Strong return on equity — 81%.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
Compiled from this issue's live GMP, subscription, valuation and financial data, and updated as those figures change. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Accretion Nutraveda, since its incorporation in 2021, has been focused on the manufacturing of Ayurvedic and Nutraceutical products in India. It offers Ayurvedic and Nutraceutical products in various dosages and forms, like tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. The company serves its customers in India as well as in international countries like Sri Lanka, Singapore, and the USA. The firm blends Ayurvedic and science to offer treatments for various areas, like liver care, women’s health, bone and joint health, cognitive support, and respiratory wellness. The company runs a 10,763 sq. ft. manufacturing facility situated in Gujarat. Its unit includes modern infrastructure and quality control systems.
Accretion Nutraveda Ltd., 27 Xcelon Industrial Park-1, Vasna-Chacharwadi, TaSanand,, Ahmedabad, Gujarat, 382213
| Purpose | Amount (Cr) |
|---|---|
| Purchase of Machineries for Automation in existing Manufacturing unit | 4.22 |
| Purchase of Machineries for New Manufacturing Setup | 8.03 |
| Funding working capital requirements of our company | 5.50 |
| General Corporate Purpose | - |
Resources & Documents
Accretion Nutraveda has set a price band of Rs 122–Rs 129 per share for an issue size of Rs 25 crore in the nutraceuticals sector. The stock listed with a 48.22% gain versus its issue price on February 04, 2026.
Accretion Nutraveda, since its incorporation in 2021, has been focused on the manufacturing of Ayurvedic and Nutraceutical products in India. It offers Ayurvedic and Nutraceutical products in various dosages and forms, like tablets, capsules, oral liquids, powders, oils, and external preparations like balms, creams, and gels. The company operates in the nutraceuticals space.
The issue is promoted by Mr. Mayur Popatlal Sojitra, Mr. Ankurkumar Shantilal Patel, Mr. Paraskumar Vinubhai Parmar, Mr. Hardik Mukundbhai Prajapati, Mr. Harshad Nanubhai Rathod & Mr. Vivek Ashok Kumar Patel with Sobhagya Capital Options Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Purchase of Machineries for Automation in existing Manufacturing unit (Rs 4 crore) and Purchase of Machineries for New Manufacturing Setup (Rs 8 crore).
On fundamentals, the company is posting revenue growth of 208.9%, a profit margin of 16.3%, return on equity of 81.2% in its most recent reported period. Listed peers in this segment include Influx Healthtech Limited (P/E 25.93x, market cap Rs 37 crore) and Walpar Nutritions Ltd. (P/E 23.94x, market cap Rs 11 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Accretion Nutraveda IPO GMP — What It Means
GMP stops mattering once the shares trade — it only ever estimated the listing price. The summary at the top of this page compares the last pre-listing GMP with how the shares actually listed.
See the full Accretion Nutraveda GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
No comments yet. Be the first to share your opinion!